You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.
The court found that the university had failed to demonstrate that one of its researchers had collaborated with the IP's inventors and therefore is not entitled to co-inventorship.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.